SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor call recording12-08-2023
12-08-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation for the quarter ended 30 June 202311-08-2023
SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Unaudited Standalone & Consolidated Financial Results For The Quarter Ended 30Th June 2023
Unaudited standalone & consolidated financial results for the quarter ended 30th june 202310-08-2023
SHILPA MEDICARE LTD. - 530549 - Unaudited Standalone & Consolidated Financial Results For The Quarter Ended 30Th June 2023
Board considered and approved the standalone & consolidated financial results for the quarter ended 30th June 202310-08-2023
SHILPA MEDICARE LTD. - 530549 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August 09, 2023 for Ramakant Innani, on behalf of Promoters09-08-2023
SHILPA MEDICARE LTD. - 530549 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August 08, 2023 for Ramakant Innani, on behalf of Promoters09-08-2023
SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 09, 2023 for Ramakant Innani, on behalf of Promoters09-08-2023
SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 08, 2023 for Ramakant Innani, on behalf of Promoters09-08-2023
SHILPA MEDICARE LTD. - 530549 - Disclosure Under Reg 30 Of SEBI (LODR) Regulations 2015
In continuation to the intimation dated 21 July 2023 with respect to issuance of non-convertible debentures by its wholly owned Subsidiaries (Shilpa Pharma Lifesciences Limited & Shilpa Biologicals Private Limited), the identified promoters of the Company have executed the Non disposal undertaking agreement dt 7th August 2023, for not transferring, selling or otherwise disposing equity shares of the Company.08-08-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q1 FY23 Conference Call to be held on Friday, August 11, 2023 at 03:00 PM IST.07-08-2023